CARsgen Therapeutics Holdings Ltd. is a clinical-stage biopharmaceutical company, which engages in discovering, researching, and developing cell therapies. The company is headquartered in Shanghai, Shanghai and currently employs 371 full-time employees. The company went IPO on 2021-06-18. The Company’s main business is engaged in developing chimeric antigen receptor T cell (CAR T) -cell therapies to address clinical needs including but not limited to hematologic malignancies solid tumors and autoimmune diseases. The Company’s main products include zevor-cel (zevorcabtagene autoleucel), satricabtagene autoleucel and allogeneic CAR T-cell products. The firm conducts its business in the domestic and overseas markets.
02171.HK stock price ended at $15.93 on 金曜日, after dropping 2.81%
On the latest trading day Jan 16, 2026, the stock price of 02171.HK fell by 2.81%, dropping from $16.39 to $15.93. During the session, the stock saw a volatility of 4.60%, with prices oscillating between a daily low of $15.87 and a high of $16.60. On the latest trading day, the trading volume for 02171.HK rose by 368.5K shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 1.1M shares were traded, with a market value of approximately $8.7B.